Media

Aro Biotherapeutics Doses First Patient in Phase 1b Trial of ABX1100 in Late-Onset Pompe Disease (LOPD)

FDA Clears Ariceum Therapeutics’ 225Ac-Satoreotide Phase I/II Clinical Study in Patients with Small Cell Lung Cancer or Merkel Cell Carcinoma

Ariceum Therapeutics and ITM Enter Supply Agreement for Therapeutic Medical Radioisotope Actinium-225

Hemab Therapeutics Expands Management Team with Appointment of Kate Madigan, MD, as Chief Medical Officer and Announce Presentation at the 43rd Annual J.P. Morgan Healthcare Conference

BONESUPPORT – CERAMENT® G AND CERAMENT® V contributes to improved survival rates

Aprea Therapeutics Announces Twice Daily (BID) Dosing of Patients in ABOYA-119 Clinical Trial of ATRN-119 to Potentially Optimize Clinical Outcomes and Strengthen Clinical Path Forward

InCarda Therapeutics Appoints Dr. Myles Greenberg as New CEO

Spruce Biosciences Announces Topline Results from CAHmelia-204 in Adult CAH and CAHptain-205 in Adult and Pediatric CAH

Ariceum Therapeutics and Eckert & Ziegler Sign Global Supply Agreement for the Development of Next-Generation Radiotherapeutics for Precision Cancer Treatments

Doctrin collaborates with Silo AI to enhance patient communication